martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

View original at finance.yahoo.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The outcome of the IRA pricing negotiations for Austedo went as expected

    80% confidence

  • Teva aims to double its global biosimilars sales by 2027

    80% confidence

  • CMS is expected to formally announce the agreement on a maximum fair price for Austedo in November 2025

    80% confidence

  • Teva anticipates generating more than $5 billion in revenues from its branded products by 2030

    80% confidence

  • Teva expects to launch Austedo in European markets in 2026

    80% confidence

  • Austedo sales expected to exceed $3 billion by 2030

    80% confidence

  • Teva expects to file a new drug application for olanzapine before the year ends

    80% confidence

  • Austedo annual revenues expected to be more than $2.5 billion by 2027

    80% confidence

  • Teva expects five additional biosimilar launches by 2027

    80% confidence

  • Teva raised its 2025 Austedo sales expectations following IRA pricing negotiations conclusion

    80% confidence

  • In 2025, Teva expects its generics business to be flat to up in low single digits in constant currency terms

    80% confidence

  • Teva is a Hold stock with Zacks Rank #3

    80% confidence

  • Teva expects an adjusted operating margin of 30% by 2027 through cost savings and continued growth of branded drugs

    80% confidence

  • Teva expects Uzedy total sales to be between $190 million and $200 million in 2025

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play — Source | Via News | es.VIA.NEWS